Belite Bio (NASDAQ:BLTE) Price Target Raised to $215.00

Key Points

• Leerink Partners raised its price target on Belite Bio to $215 from $185, maintaining an “outperform” rating; the new target implies 28.95% upside from the prior close.
• Analyst sentiment is broadly positive: the consensus rating is “Moderate Buy” with an average target of $226.27, while nine analysts rate the stock Buy, two Hold, and one Sell.
• Belite shares fell 1.9% to $166.73 on Friday. The company reported a quarterly loss of $0.60 per share, narrower than the $0.79 loss analysts expected.

Belite Bio (NASDAQ:BLTE - Get Free Report) had its target price increased by equities researchers at Leerink Partners from $185.00 to $215.00 in a report released on Friday, Benzinga reports. The firm presently has an "outperform" rating on the stock. Leerink Partners's price objective would suggest a potential upside of 28.95% from the stock's previous close.

Other analysts have also issued reports about the company. Canaccord Genuity Group started coverage on Belite Bio in a report on Friday, September 4th. They set a "buy" rating and a $303.00 price objective for the company. UBS Group reiterated a "buy" rating on shares of Belite Bio in a report on Thursday, September 3rd. Jefferies Financial Group reissued a "hold" rating on shares of Belite Bio in a research report on Wednesday, September 9th. Zacks Research cut Belite Bio from a "strong-buy" rating to a "hold" rating in a research note on Tuesday, August 18th. Finally, HC Wainwright reaffirmed a "buy" rating and set a $245.00 price objective on shares of Belite Bio in a report on Thursday, October 15th. Nine equities research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, Belite Bio currently has an average rating of "Moderate Buy" and a consensus target price of $226.27.

Belite Bio Stock Down 1.9%

Belite Bio stock traded down $3.23 during trading hours on Friday, hitting $166.73. The stock had a trading volume of 181,270 shares, compared to its average volume of 190,771. The business's 50 day simple moving average is $161.02 and its 200-day simple moving average is $160.25. Belite Bio has a one year low of $105.88 and a one year high of $200.00. The stock has a market cap of $6.71 billion, a price-to-earnings ratio of -61.07 and a beta of -1.19.

Belite Bio (NASDAQ:BLTE - Get Free Report) last announced its earnings results on Thursday, November 12th. The company reported ($0.60) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.79) by $0.19. Research analysts anticipate that Belite Bio will post -3.08 EPS for the current fiscal year.

Insider Activity at Belite Bio

In other Belite Bio news, CFO Hao-Yuan Chuang sold 49,433 shares of the stock in a transaction that occurred on Friday, September 4th. The shares were sold at an average price of $187.64, for a total value of $9,275,608.12. Following the sale, the chief financial officer directly owned 44,000 shares in the company, valued at $8,256,160. This represents a 52.91% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CEO Yu-Hsin Lin sold 74,435 shares of Belite Bio stock in a transaction on Friday, September 4th. The shares were sold at an average price of $187.71, for a total value of $13,972,193.85. Following the sale, the chief executive officer directly owned 96,134 shares of the company's stock, valued at $18,045,313.14. This represents a 43.64% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last ninety days, insiders sold 168,330 shares of company stock worth $31,969,118. Corporate insiders own 13.29% of the company's stock.

Institutional Investors Weigh In On Belite Bio

A number of institutional investors have recently made changes to their positions in the business. Affinity Asset Advisors LLC raised its stake in Belite Bio by 225.0% in the first quarter. Affinity Asset Advisors LLC now owns 65,000 shares of the company's stock worth $10,364,000 after buying an additional 45,000 shares in the last quarter. Candriam S.C.A. bought a new stake in Belite Bio during the 3rd quarter valued at approximately $10,711,000. Renaissance Technologies LLC bought a new stake in Belite Bio during the 1st quarter valued at approximately $8,291,000. The Manufacturers Life Insurance Company purchased a new position in shares of Belite Bio during the 1st quarter worth approximately $3,125,000. Finally, Amundi purchased a new position in shares of Belite Bio during the 1st quarter worth approximately $671,000. Hedge funds and other institutional investors own 0.53% of the company's stock.

Top Belite Bio Stories

Here are a few of the latest stories about BLTE:

• Positive Sentiment: The FDA accepted Belite Bio’s tinlarebant NDA for priority review, moving the drug closer to a potential first-ever treatment for Stargardt disease. This regulatory milestone may support investor optimism as the FDA review proceeds. Belite Bio Q3 2026 Earnings Call Highlights
• Positive Sentiment: A technical analysis article said shares moved above their 200-day moving average, a trend signal that some investors may view positively. BLTE share price and 200-day moving average
• Negative Sentiment: Belite Bio reported a $30.3 million quarterly net loss. The loss underscores the costs and uncertainty involved in advancing its drug pipeline; the company has not yet established a commercial revenue base. Belite Bio reveals quarterly loss

About Belite Bio

Belite Bio, Inc. is a clinical-stage biopharmaceutical company developing treatments for retinal and metabolic diseases. The company focuses on conditions with limited treatment options, including inherited retinal disorders and age-related eye disease. Its lead drug candidate, tinlarebant, is an oral therapy designed to reduce the accumulation of toxic vitamin A byproducts in the retina. Belite Bio is evaluating tinlarebant for Stargardt disease and geographic atrophy associated with dry age-related macular degeneration.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.